NasdaqGS - Delayed Quote USD

Metsera, Inc. (MTSR)

28.12

+1.40

+(5.24%)

At close: 4:00:01 PM EDT

29.00

+0.88

+(3.13%)

After hours: 5:43:26 PM EDT

Metsera Reports First Quarter 2025 Financial Results and Continued Portfolio Progress

MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is in three ongoing VESPER Phase 2b trials, with data from VESPER-1 expected in mid-2025 MET-233i, a monthly, ultra-long acting amylin analog, is in Phase 1 trials as a monotherapy and co-administered with MET-097i, with five-week monotherapy data expected in Q2 2025MET-097o, an oral formulation of MET-097i, has been accelerated and alternate oral candidate MET-224o is on track, with four-week data for selected lead exp

GlobeNewswire 21 days ago

MTSR
+5.24%
Metsera to Present at Bank of America 2025 Global Healthcare Conference

NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR) (“Metsera” or the “Company”), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today announced that Whit Bernard, its Chief Executive Officer, will present at the Bank of America 2025 Global Healthcare Conference on Wednesday, May 14 at 2:20 - 2:35 P.M. PDT (5:20 – 5:35 P.M. EDT). A live webcast of the presentation will be available on the Events pag

GlobeNewswire 25 days ago

MTSR
+5.24%
Metsera Reports Fourth Quarter and Full Year 2024 Financial Results and Continued Portfolio Progress

MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is being studied in multiple Phase 2b clinical trials with read-outs beginning mid-2025 Multiple data readouts in mid and late 2025 on track for MET-233i, an ultra-long acting amylin analog currently in Phase 1 Oral formulation optimization study on track to support initiation of clinical trials for MET-224o and MET097o, with MET-224o data expected in late 2025 Completed IPO with gross proceeds of approximately $316.2 m

GlobeNewswire 2 months ago

MTSR
+5.24%
Metsera, Inc. (MTSR): Among Top Insider Purchases Last Month

We recently published a list of Top 10 Insider Purchases Last Month. In this article, we are going to take a look at where Metsera, Inc. (NASDAQ:MTSR) stands against other top insider purchases last month. Will there be a recession? How will new tariffs impact the U.S. economy? What’s next on President Trump’s geopolitical agenda? […]

Insider Monkey 2 months ago

MTSR
+5.24%
Is Metsera, Inc. (MTSR) Among Stocks With At Least $20 Million In Insider Spending Recently?

We recently published a list of 10 Stocks With At Least $20 Million In Insider Spending Recently. In this article, we are going to take a look at where Metsera, Inc. (NASDAQ:MTSR) stands against other stocks with at least $20 million in insider spending recently. As the stock market navigates a complex environment shaped by […]

Insider Monkey 2 months ago

MTSR
+5.24%
Metsera, Inc. (MTSR): Among Stocks With At Least $10 Million In Insider Spending Recently

We recently published a list of 10 Stocks With At Least $10 Million In Insider Spending Recently. In this article, we are going to take a look at where Metsera, Inc. (NASDAQ:MTSR) stands against other stocks with at least $10 million in insider spending recently. Since Donald Trump took office, the stock market has experienced […]

Insider Monkey 2 months ago

MTSR
+5.24%
Metsera to Present at TD Cowen’s 45th Annual Health Care Conference

NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR) (“Metsera” or the “Company”), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today announced that Whit Bernard, its Chief Executive Officer, will present at TD Cowen’s 45th Annual Health Care Conference on Tuesday, March 4, 2025, from 1:10 – 1:40 p.m. ET. A live webcast of the presentation will be available on the Events page in the Investors & Ne

GlobeNewswire 3 months ago

MTSR
+5.24%
Wall Street bullish on Metsera following January IPO on obesity drug pipeline

Investing.com -- Wall Street analysts initiated coverage on Metsera with bullish outlook given the biotech firm’s differentiated obesity drug pipeline and potential for significant upside. Metsera is also viewed as a potential acquisition target for larger biopharma firms looking to enter the obesity market.

Investing.com 3 months ago

MTSR
+5.24%
Metsera (MTSR): Among Stocks Insiders Spent The Most Money On Recently

We recently published a list of 10 Stocks Insiders Spent The Most Money On Recently. In this article, we are going to take a look at where Metsera (NASDAQ:MTSR) stands against other stocks insiders spent the most money on recently. As the broader market continues to rise this year, we thought it would be interesting […]

Insider Monkey 3 months ago

MTSR
+5.24%
Metsera Announces Closing of Initial Public Offering and Full Exercise and Closing of Underwriters’ Option to Purchase Additional Shares

NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR) (“Metsera”), a clinical-stage biotechnology company developing next-generation injectable and oral nutrient stimulated hormone (NuSH) analog peptides to treat obesity, overweight and related conditions, announced the closing of its initial public offering of 15,277,778 shares of its common stock, at an initial public offering price of $18.00 per share, on February 3, 2025. In addition, Metsera today announced the exercise i

GlobeNewswire 3 months ago

MTSR
+5.24%
Metsera Announces Pricing of Initial Public Offering

NEW YORK, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR) (“Metsera”), a clinical-stage biotechnology company developing next-generation injectable and oral nutrient stimulated hormone (NuSH) analog peptides to treat obesity, overweight and related conditions, today announced the pricing of its initial public offering of 15,277,778 shares of its common stock at a price to the public of $18.00 per share. All of the shares of common stock are being offered by Metsera. The gross proc

GlobeNewswire 3 months ago

MTSR
+5.24%
Metsera, Maze secure combined $415 million in IPOs

The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go public.

BioPharma Dive 3 months ago

MTSR
+5.24%

MAZE

Performance Overview

Return	MTSR	S&P 500 (^GSPC)
YTD	+10.27%	+0.92%
1-Year	+10.27%	+12.48%
3-Year	+10.27%	+42.12%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Metsera, Inc. (MTSR)

Metsera Reports First Quarter 2025 Financial Results and Continued Portfolio Progress

Metsera to Present at Bank of America 2025 Global Healthcare Conference

Metsera Reports Fourth Quarter and Full Year 2024 Financial Results and Continued Portfolio Progress

Metsera, Inc. (MTSR): Among Top Insider Purchases Last Month

Is Metsera, Inc. (MTSR) Among Stocks With At Least $20 Million In Insider Spending Recently?

Metsera, Inc. (MTSR): Among Stocks With At Least $10 Million In Insider Spending Recently

Metsera to Present at TD Cowen’s 45th Annual Health Care Conference

Wall Street bullish on Metsera following January IPO on obesity drug pipeline

Metsera (MTSR): Among Stocks Insiders Spent The Most Money On Recently

Metsera Announces Closing of Initial Public Offering and Full Exercise and Closing of Underwriters’ Option to Purchase Additional Shares

Metsera Announces Pricing of Initial Public Offering

Metsera, Maze secure combined $415 million in IPOs

Performance Overview